Breaking News Instant updates and real-time market news.

ASLN

Aslan Pharmaceuticals

$1.73

-0.09 (-4.95%)

05:25
09/30/19
09/30
05:25
09/30/19
05:25

Aslan Pharmaceuticals, Bukwang Pharmaceutical establish JV

Aslan Pharmaceuticals and Bukwang Pharmaceutical announced that they have established a new joint venture to develop preclinical aryl hydrocarbon receptor, or AhR, antagonists from ASLAN's early stage pipeline. The independent company, JAGUAHR Therapeutics, will focus on developing new immuno-oncology therapeutics for global markets targeting the AhR pathway and will be based in Singapore. Under the terms of the agreement, ASLAN will transfer the global rights to all of the assets related to AhR technology, originally discovered and developed by ASLAN and its collaborator Dr Mark Graham, into JAGUAHR. Bukwang will invest $5M in JAGUAHR in two tranches to fund the development of the assets, identify a lead development compound and file an Investigational New Drug application.

ASLN Aslan Pharmaceuticals
$1.73

-0.09 (-4.95%)

01/14/19
HCWC
01/14/19
NO CHANGE
Target $8.5
HCWC
Buy
Aslan Pharmaceuticals price target lowered to $8.50 from $12 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju lowered his price target for Aslan Pharmaceuticals to $8.50 after varlitinib data in first-line gastric cancer didn't show statistical significance. The analyst, however, reiterates a Buy rating on the shares.
01/15/19
PIPR
01/15/19
NO CHANGE
Target $7
PIPR
Overweight
Aslan achieved 'impressive' overall response rate in BTC, says Piper Jaffray
Aslan Pharmaceuticals' varlitinib added to gemcitabine and cisplatine achieved an "impressive" overall response rate of 43.8% and disease control rate of 93.8% in the Phase Ib/II study in first-line biliary tract cancer, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. Varlitinib was also well tolerated with the most common adverse events decreases in platelet and neutrophil counts, adds the analyst. The data presented last night increase his confidence in the fully-enrolled Phase III TreeTopp trial of varlitinib in second line biliary tract cancer with top-line data in the second half of 2019. He reiterates an Overweight rating on Aslan Pharmaceuticals with a $7 price target.
01/30/19
PIPR
01/30/19
NO CHANGE
Target $7
PIPR
Overweight
Piper Jaffray reiterates Overweight rating on Aslan after restructuring news
After Aslan Pharmaceuticals announced it is conducting a corporate restructuring that will cut headcount by 30% and operating costs by 50%, Piper Jaffray analyst Edward Tenthoff noted the restructuring does not impact development of wholly-owned varlitinib in biliary tract cancer, ASLAN003 in acute myeloid leukemia and ASLAN004 in atopic dermatitis. Tenthoff, who said the primary driver for varlitinib remains Phase 3 TreeTopp trial data in the second half of 2019, reiterates an Overweight rating and $7 price target on Aslan shares.
04/01/19
PIPR
04/01/19
NO CHANGE
Target $7
PIPR
Overweight
Aslan data show comparable activity to Dupixent, says Piper Jaffray
Aslan Pharmaceuticals reported preliminary Phase I single-ascending dose data on intravenous ASLAN004 demonstrating the IL13 receptor antibody to be safe and well tolerated in healthy volunteers with no discontinuations due to adverse events, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. ASLAN004 caused complete inhibition of phosphorylation of STAT6 within one hour lasting for greater than 29 days, adds the analyst. He believes these results present the opportunity for once-monthly dosing of ASLAN004 with comparable activity to Regeneron's (REGN) Dupixent. Tenthoff reiterates an Overweight rating on Aslan Pharmaceuticals with a $7 price target.

TODAY'S FREE FLY STORIES

GLD

SPDR Gold Shares

$137.98

0.56 (0.41%)

18:03
11/13/19
11/13
18:03
11/13/19
18:03
Hot Stocks
SPDR Gold Shares holdings fall to 896.77MT from 897.09MT »

This is the second…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPA

Copa Holdings

$107.71

1.89 (1.79%)

17:57
11/13/19
11/13
17:57
11/13/19
17:57
Hot Stocks
Copa Holdings reports October capacity down 4.8%, traffic down 1.4% »

Copa Holdings released…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 03

    Dec

CCI

Crown Castle

$131.34

0.67 (0.51%)

17:51
11/13/19
11/13
17:51
11/13/19
17:51
Hot Stocks
Crown Castle chairman buys 10.9K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

GOOG

Alphabet

$1,298.00

-0.77 (-0.06%)

, GOOGL

Alphabet Class A

$1,296.00

-1.18 (-0.09%)

17:48
11/13/19
11/13
17:48
11/13/19
17:48
Periodicals
Google confirms several features not available on Stadia at launch, Kotaku says »

During an AMA on Reddit,…

GOOG

Alphabet

$1,298.00

-0.77 (-0.06%)

GOOGL

Alphabet Class A

$1,296.00

-1.18 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAESY

BAE Systems

$0.00

(0.00%)

17:44
11/13/19
11/13
17:44
11/13/19
17:44
Hot Stocks
BAE Systems awarded maximum $270.6M Navy contract modification »

BAE Systems was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBT

HBT Financial

$16.99

0.18 (1.07%)

17:38
11/13/19
11/13
17:38
11/13/19
17:38
Hot Stocks
HBT Financial director Patrick Busch buys over 13K shares of company stock »

HBT Financial director…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMO

Thermo Fisher

$299.90

3.82 (1.29%)

, QGEN

Qiagen

$35.52

3.26 (10.11%)

17:38
11/13/19
11/13
17:38
11/13/19
17:38
Periodicals
Thermo Fisher considering purchase of Qiagen, Bloomberg reports »

Thermo Fisher (TMO) is…

TMO

Thermo Fisher

$299.90

3.82 (1.29%)

QGEN

Qiagen

$35.52

3.26 (10.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 07

    Dec

AOBC

American Outdoor Brands

$7.90

0.22 (2.86%)

17:36
11/13/19
11/13
17:36
11/13/19
17:36
Conference/Events
American Outdoor Brands to hold a conference call »

President & CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRK

Comstock Resources

$7.18

0.3 (4.36%)

17:33
11/13/19
11/13
17:33
11/13/19
17:33
Syndicate
Breaking Syndicate news story on Comstock Resources »

Comstock Resources files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SU

Suncor

$31.90

0.02 (0.06%)

17:32
11/13/19
11/13
17:32
11/13/19
17:32
Hot Stocks
Suncor increases share repurchase program by $500M »

Suncor's board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 19

    Nov

VRRM

Verra Mobility

$14.70

0.045 (0.31%)

17:24
11/13/19
11/13
17:24
11/13/19
17:24
Syndicate
Verra Mobility files to sell 15M shares of Class A common stock for holders »

Morgan Stanley is acting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

EQ

Equillium

$3.20

-0.19 (-5.60%)

17:22
11/13/19
11/13
17:22
11/13/19
17:22
Syndicate
Breaking Syndicate news story on Equillium »

Equillium files $250M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

PAG

Penske Automotive

$51.36

0.015 (0.03%)

17:13
11/13/19
11/13
17:13
11/13/19
17:13
Syndicate
Breaking Syndicate news story on Penske Automotive »

Penske Automotive files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

LLY

Eli Lilly

$112.85

-0.31 (-0.27%)

17:12
11/13/19
11/13
17:12
11/13/19
17:12
Hot Stocks
FDA committee says benefits of empagliflozin do not outweigh risks »

The FDA Endocrinologic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

PRTH

Priority Technology

$3.24

-0.03 (-0.92%)

17:08
11/13/19
11/13
17:08
11/13/19
17:08
Earnings
Priority Technology reports Q3 EPS (9c), one estimate (12c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPZ

Domino's Pizza

$279.24

1.185 (0.43%)

17:07
11/13/19
11/13
17:07
11/13/19
17:07
Hot Stocks
Domino's Pizza's Goldman sells 2,486 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 11

    Dec

  • 12

    Dec

WE

We Company

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

17:04
11/13/19
11/13
17:04
11/13/19
17:04
Periodicals
WeWork reported $1.25B loss in Q3, NY Times reports »

WeWork (WE) lost $1.25B…

WE

We Company

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLYC

GlycoMimetics

$6.27

0.31 (5.20%)

17:02
11/13/19
11/13
17:02
11/13/19
17:02
Initiation
GlycoMimetics initiated  »

GlycoMimetics resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLK

BlackRock

$485.67

-1.24 (-0.25%)

17:00
11/13/19
11/13
17:00
11/13/19
17:00
Hot Stocks
BlackRock CFO sells nearly 4,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

ARVN

Arvinas

$28.35

1.85 (6.98%)

16:58
11/13/19
11/13
16:58
11/13/19
16:58
Initiation
Arvinas initiated  »

Arvinas initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FEYE

FireEye

$17.09

-0.04 (-0.23%)

16:57
11/13/19
11/13
16:57
11/13/19
16:57
Recommendations
FireEye analyst commentary  »

FireEye unique offering…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

CSCO

Cisco

$48.44

0.06 (0.12%)

16:54
11/13/19
11/13
16:54
11/13/19
16:54
Hot Stocks
Cisco says cyber security is a top priority for customers »

Says innovation pipeline…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 09

    Dec

  • 10

    Dec

JPM

JPMorgan

$128.49

-0.65 (-0.50%)

16:54
11/13/19
11/13
16:54
11/13/19
16:54
Periodicals
JPMorgan's new HQ plan clears path for another NYC tower, Bloomberg says »

JPMorgan's plan to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 14

    Jan

SIBN

SI-Bone

$17.88

0.14 (0.79%)

16:53
11/13/19
11/13
16:53
11/13/19
16:53
Syndicate
Breaking Syndicate news story on SI-Bone »

SI-Bone files $200M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPA

Copa Holdings

$107.71

1.89 (1.79%)

16:52
11/13/19
11/13
16:52
11/13/19
16:52
Hot Stocks
Copa Holdings reports Q3 load factor up 1.4pts to 85.6% »

Copa Holdings reports Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 03

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.